ArticleNature medicine2024
Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping.
Abstract readPublished Erratum
In one paragraph
Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
Corrections and comments
- Erratum for
Authors and funding
43 authors.
Sylvan C BacaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ji-Heui SeoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Matthew P DavidsohnDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Brad FortunatoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Karl SemaanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Shahabbedin SotudianDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5864-6192
Gitanjali LakshminarayananDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Miklos DiossyComputational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA.
Xintao QiuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8560-7017
Talal El ZarifDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Hunter SavignanoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
John CanniffDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ikenna MaduekeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Renee Maria SalibyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9241-597X
Ziwei ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Rong LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0009-0000-1046-9580
Yijia JiangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Len TaingDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Mark AwadLowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Cindy H ChauMolecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-6928-3833
James A DeCaprioDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0896-167X
William D FiggMolecular Pharmacology Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-2428-5613
Tim F GretenLiver Cancer Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-0806-2535
Aaron N HataMassachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6127-318X
F Stephen HodiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Melissa E HughesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Keith L LigonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7733-600X
Nancy LinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kimmie NgDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-0631-1494
Matthew G OserDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0003-2047-0969
Catherine MeadorMassachusetts General Hospital Cancer Center, Boston, MA, USA.
Heather A ParsonsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-8178-6612
Mark M PomerantzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Arun RajanThoracic and Gastrointestinal Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-2776-3385
Jerome RitzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5526-4669
Manisha ThakuriaDepartment of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Sara M TolaneyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5940-8671
Patrick Y WenCenter for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Henry LongDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6849-6629
Jacob E BerchuckDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7607-2428
Zoltan SzallasiComputational Health Informatics Program, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5395-7509
Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9201-3217
Matthew L FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. matthew_freedman@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-0151-1238
Funding
Identify SNPs and Polymorphisms Involved in the Development of Prostate CancerZIABC010453 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FIGG, WILLIAM DOUGLAS · 2009 to 2025
$10.4MAbstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.